Nesrin Ocal, Aykut Cilli, Nesrin Mogulkoc, Funda Coskun, Ahmet Ursavas, Ismail Hanta, Berna Akinci Ozyurek, Kerem Ensarioglu, Alper Ezircan, Esra Yuksel, Beste Arikan, Fatih Uzer, Tugce Sahin Ozdemirel, Salim Misirci, Pelin Pinar Deniz, Ilknur Basyigit, Ozlem Ozdemir Kumbasar
{"title":"进行性非特发性肺纤维化患者接受抗纤维化治疗的疗效、耐受性和生存率分析。","authors":"Nesrin Ocal, Aykut Cilli, Nesrin Mogulkoc, Funda Coskun, Ahmet Ursavas, Ismail Hanta, Berna Akinci Ozyurek, Kerem Ensarioglu, Alper Ezircan, Esra Yuksel, Beste Arikan, Fatih Uzer, Tugce Sahin Ozdemirel, Salim Misirci, Pelin Pinar Deniz, Ilknur Basyigit, Ozlem Ozdemir Kumbasar","doi":"10.4103/atm.atm_213_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There are still disagreements about diagnostic criteria and treatment of progressive pulmonary fibrosis (PPF). Real-life data and survival analyses have a guiding role in clarifying this issue.</p><p><strong>Methods: </strong>In this multicenter retrospective cohort study, real-life data of adult patients diagnosed with PPF and treated with antifibrotics for at least 6 months were examined.</p><p><strong>Results: </strong>Of the 222 patients, 161 were treated with Nintedanib (N) and 61 with Pirfenidone (P). The most common PPF subtype was connective tissue disease-related interstitial lung disease (CTD-ILD) (53.2%). The progression rate was significantly higher in patients with usual interstitial pneumonia (UIP) (<i>P</i> = 0.003). A -3.1% (-49.2 ml) decrease was detected in forced vital capacity (FVC) in the 6<sup>th</sup> month. The 6<sup>th</sup> month and overall progression-free survival (PFS) rates were 83.3% and 51.8%. The 6<sup>th</sup> month and overall clinical event-free survival (CEFS) rates were 89.6% and 53.6%. The survival rates for 6<sup>th</sup>, 12<sup>th</sup>, and entire follow-up periods were found to be 98.2%, 89.2%, and 77.5%. CT-ILD had the longest survival time (166.5 ± 9.2 months) and fibrotic hypersensitivity pneumonia had the shortest survival time (87.6 ± 9.2 months) (<i>P</i> = 0.011). N was advantageous in patients with UIP in terms of FVC loss and estimated survival. While PFS during the entire follow-up period was in favor of N, CEFS had no significant difference between drugs.</p><p><strong>Conclusion: </strong>PPF subtypes have significant differences in terms of prognosis and survival. The effect of AF drugs on progression varies, especially among radiological patterns. An individualized approach is required in the diagnosis, follow-up, and treatment of patients with PPF.</p>","PeriodicalId":50760,"journal":{"name":"Annals of Thoracic Medicine","volume":"20 2","pages":"98-107"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11996130/pdf/","citationCount":"0","resultStr":"{\"title\":\"Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis.\",\"authors\":\"Nesrin Ocal, Aykut Cilli, Nesrin Mogulkoc, Funda Coskun, Ahmet Ursavas, Ismail Hanta, Berna Akinci Ozyurek, Kerem Ensarioglu, Alper Ezircan, Esra Yuksel, Beste Arikan, Fatih Uzer, Tugce Sahin Ozdemirel, Salim Misirci, Pelin Pinar Deniz, Ilknur Basyigit, Ozlem Ozdemir Kumbasar\",\"doi\":\"10.4103/atm.atm_213_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>There are still disagreements about diagnostic criteria and treatment of progressive pulmonary fibrosis (PPF). Real-life data and survival analyses have a guiding role in clarifying this issue.</p><p><strong>Methods: </strong>In this multicenter retrospective cohort study, real-life data of adult patients diagnosed with PPF and treated with antifibrotics for at least 6 months were examined.</p><p><strong>Results: </strong>Of the 222 patients, 161 were treated with Nintedanib (N) and 61 with Pirfenidone (P). The most common PPF subtype was connective tissue disease-related interstitial lung disease (CTD-ILD) (53.2%). The progression rate was significantly higher in patients with usual interstitial pneumonia (UIP) (<i>P</i> = 0.003). A -3.1% (-49.2 ml) decrease was detected in forced vital capacity (FVC) in the 6<sup>th</sup> month. The 6<sup>th</sup> month and overall progression-free survival (PFS) rates were 83.3% and 51.8%. The 6<sup>th</sup> month and overall clinical event-free survival (CEFS) rates were 89.6% and 53.6%. The survival rates for 6<sup>th</sup>, 12<sup>th</sup>, and entire follow-up periods were found to be 98.2%, 89.2%, and 77.5%. CT-ILD had the longest survival time (166.5 ± 9.2 months) and fibrotic hypersensitivity pneumonia had the shortest survival time (87.6 ± 9.2 months) (<i>P</i> = 0.011). N was advantageous in patients with UIP in terms of FVC loss and estimated survival. While PFS during the entire follow-up period was in favor of N, CEFS had no significant difference between drugs.</p><p><strong>Conclusion: </strong>PPF subtypes have significant differences in terms of prognosis and survival. The effect of AF drugs on progression varies, especially among radiological patterns. An individualized approach is required in the diagnosis, follow-up, and treatment of patients with PPF.</p>\",\"PeriodicalId\":50760,\"journal\":{\"name\":\"Annals of Thoracic Medicine\",\"volume\":\"20 2\",\"pages\":\"98-107\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11996130/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Thoracic Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/atm.atm_213_24\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Thoracic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/atm.atm_213_24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis.
Background: There are still disagreements about diagnostic criteria and treatment of progressive pulmonary fibrosis (PPF). Real-life data and survival analyses have a guiding role in clarifying this issue.
Methods: In this multicenter retrospective cohort study, real-life data of adult patients diagnosed with PPF and treated with antifibrotics for at least 6 months were examined.
Results: Of the 222 patients, 161 were treated with Nintedanib (N) and 61 with Pirfenidone (P). The most common PPF subtype was connective tissue disease-related interstitial lung disease (CTD-ILD) (53.2%). The progression rate was significantly higher in patients with usual interstitial pneumonia (UIP) (P = 0.003). A -3.1% (-49.2 ml) decrease was detected in forced vital capacity (FVC) in the 6th month. The 6th month and overall progression-free survival (PFS) rates were 83.3% and 51.8%. The 6th month and overall clinical event-free survival (CEFS) rates were 89.6% and 53.6%. The survival rates for 6th, 12th, and entire follow-up periods were found to be 98.2%, 89.2%, and 77.5%. CT-ILD had the longest survival time (166.5 ± 9.2 months) and fibrotic hypersensitivity pneumonia had the shortest survival time (87.6 ± 9.2 months) (P = 0.011). N was advantageous in patients with UIP in terms of FVC loss and estimated survival. While PFS during the entire follow-up period was in favor of N, CEFS had no significant difference between drugs.
Conclusion: PPF subtypes have significant differences in terms of prognosis and survival. The effect of AF drugs on progression varies, especially among radiological patterns. An individualized approach is required in the diagnosis, follow-up, and treatment of patients with PPF.
期刊介绍:
The journal will cover studies related to multidisciplinary specialties of chest medicine, such as adult and pediatrics pulmonology, thoracic surgery, critical care medicine, respiratory care, transplantation, sleep medicine, related basic medical sciences, and more. The journal also features basic science, special reports, case reports, board review , and more. Editorials and communications to the editor that explore controversial issues and encourage further discussion by physicians dealing with chest medicine.